Alphatec Holdings Reports Third Quarter Financial Growth
Alphatec Holdings, Inc. (NASDAQ: ATEC), a pioneering leader in spine surgery innovation, has released its financial results for the recently concluded quarter. The company continues to exceed expectations with strong revenue growth, reflecting the success of its strategic initiatives aimed at enhancing spine care.
Financial Performance in Q3 2024
Revenue and Earnings Overview
For the quarter ending September 30, 2024, Alphatec reported total revenue reaching an impressive $151 million. This figure marks a significant increase, symbolizing the company's continued ascent in the competitive medical device landscape. The GAAP gross margin stood at 68%, closely followed by a non-GAAP gross margin of 69%, showcasing operational efficiency.
Operating Expense Insights
Despite the high revenue, Alphatec experienced a GAAP net loss of $40 million during this period. The company's operating expenses, classified under GAAP, were recorded at $136 million, whereas the non-GAAP operating expenses were notably lower at $114 million. This strategic management of expenses reflects Alphatec’s commitment to financial prudence while maintaining growth.
Highlights and Strategic Initiatives
Recent Corporate Achievements
The company achieved remarkable milestones within the quarter, including a notable 20% increase in procedural volume, primarily driven by the accelerated adoption of its PTPTM and LTPTM systems. In addition, a 19% surge in new surgeon adoption signifies strong market traction.
Pivotal to the company’s growth strategy has been the expansion of its U.S. footprint, facilitating over 200 surgeon training sessions, a critical aspect of its ongoing commitment to superior medical education and practice. Alphatec has also succeeded in reducing free cash use to $21 million as it approaches the final stages of its accelerated investment phase.
Enhanced Debt Facility for Future Growth
Alphatec has taken proactive steps to fortify its financial position by expanding its existing term debt facility by $50 million, bringing its total capacity to $200 million. As a result of this transaction, the company maintains a pro forma cash balance of approximately $128 million, which will support ongoing operations and strategic initiatives.
Pedro Gonzalez de Cosio, CEO of Pharmakon Advisors, expressed optimism regarding Alphatec's trajectory, emphasizing that the company’s commitment to improving spine care is the driving force behind its sustained growth.
Full-Year 2024 Financial Outlook
Looking ahead, Alphatec now anticipates total revenue growth of 25% for the fiscal year ending December 31, 2024, projecting total revenue to reach approximately $605 million. Notably, surgical revenue is expected to contribute $540 million, bolstered by a target of $65 million from EOS revenue. The adjusted EBITDA is projected to be around $27 million for the year.
Live Webcast Presentation
To engage its investors, Alphatec will present these pivotal financial results via a live webcast. Interested parties can access the event through the Investor Relations section on the company’s official website.
Explaining Non-GAAP Financial Metrics
Alphatec’s financial statements comply with GAAP; however, the company also provides non-GAAP metrics to offer a clearer picture of its operational performance. Notable adjustments include non-GAAP gross margin and operating expenses, providing investors with complementary insights into profitability and cash flow potential.
About Alphatec Holdings, Inc.
Alphatec Holdings, Inc. is driven by a mission to revolutionize spine surgery with innovative, clinically distinct solutions, including the AlphaInformatiX Platform—a powerful tool designed to assist surgeons in enhancing patient outcomes. ATEC aims to be the leader in spine care innovation.
Frequently Asked Questions
1. What was Alphatec's total revenue for Q3 2024?
Alphatec reported total revenue of $151 million for the quarter ending September 30, 2024.
2. How has Alphatec's procedural volume changed?
The company achieved a 20% growth in procedural volume, indicating strong product adoption.
3. What is the expectation for Alphatec's full-year revenue growth?
Alphatec is forecasting a revenue growth of 25%, aiming for approximately $605 million.
4. What strategies are being implemented to manage expenses?
Alphatec has reported a decrease in free cash use and is focusing on aligning its operating expenses with its strategic goals.
5. How is the company investing in training for surgeons?
The company has expanded its training programs, engaging over 200 surgeons, thus reinforcing its commitment to education in spine care.
